Q1 Earnings Estimate for Q32 Bio Issued By Leerink Partnrs

Q32 Bio Inc. (NASDAQ:QTTB) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Q32 Bio in a research note issued on Monday, February 10th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($1.22) for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. Leerink Partnrs also issued estimates for Q32 Bio’s Q2 2025 earnings at ($1.24) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($4.04) EPS, FY2026 earnings at ($2.36) EPS, FY2027 earnings at ($3.28) EPS, FY2028 earnings at ($3.00) EPS and FY2029 earnings at ($1.50) EPS.

A number of other research firms have also recently issued reports on QTTB. Piper Sandler cut shares of Q32 Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $20.00 to $4.00 in a research report on Tuesday. Leerink Partners reiterated a “market perform” rating and issued a $9.00 price target (down previously from $68.00) on shares of Q32 Bio in a report on Wednesday, December 11th. BMO Capital Markets cut Q32 Bio from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $22.00 to $3.00 in a research note on Tuesday. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $16.00 target price (down from $95.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Finally, Raymond James reissued an “outperform” rating and issued a $22.00 price target (down previously from $90.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Q32 Bio has a consensus rating of “Hold” and a consensus target price of $24.86.

Q32 Bio Stock Down 7.6 %

Shares of NASDAQ QTTB opened at $2.66 on Thursday. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.61. The firm has a market cap of $32.40 million, a PE ratio of -0.19 and a beta of -0.32. The company’s fifty day simple moving average is $5.04 and its 200 day simple moving average is $28.35. Q32 Bio has a 12-month low of $2.59 and a 12-month high of $53.79.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QTTB. Point72 Asset Management L.P. purchased a new stake in Q32 Bio in the 3rd quarter valued at about $3,422,000. FMR LLC lifted its holdings in Q32 Bio by 137.3% during the third quarter. FMR LLC now owns 426,302 shares of the company’s stock worth $19,022,000 after acquiring an additional 246,664 shares during the period. Barclays PLC boosted its position in Q32 Bio by 105.2% in the third quarter. Barclays PLC now owns 10,443 shares of the company’s stock worth $465,000 after purchasing an additional 5,353 shares during the last quarter. Geode Capital Management LLC grew its stake in Q32 Bio by 22.4% in the 3rd quarter. Geode Capital Management LLC now owns 131,768 shares of the company’s stock valued at $5,881,000 after purchasing an additional 24,114 shares during the period. Finally, Franklin Resources Inc. purchased a new stake in shares of Q32 Bio during the 3rd quarter valued at $225,000. 31.32% of the stock is currently owned by hedge funds and other institutional investors.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.